Table 5. Non-standard diagnosis and treatment in breast cancer patients in Beijing, 2008.
| Number of cases | % | |
|---|---|---|
| Immunohistochemistry examination | ||
| ER | ||
| No test | 243/3473 | 7.00 |
| PR | ||
| No test | 245/3473 | 7.05 |
| Her-2 | ||
| No test | 309/3473 | 8.90 |
| Pathological examination | ||
| No histopathological examination | 21/3473 | 0.60 |
| No histopathological grading | 1090/2805 | 38.86 |
| No tumor size | 830/3452 | 24.04 |
| Peritumoral vascular invasion (unknown) | 2320/3452 | 67.21 |
| Lymph nodes metastasis (unknown) | 265/3452 | 7.68 |
| Treatment | ||
| Surgery | ||
| BCS without mammography | 323/819 | 39.44 |
| ALND | 105/160 | 65.63 |
| BCS without radiotherapy | 212/819 | 25.89 |
| Radiotherapy | ||
| BCS without radiotherapy | 316/819 | 38.58 |
| After mastectomy if indicated without radiotherapy |
2662/435 | 60.23 |
| Chemotherapy | ||
| DCIS with chemotherapy | 59/160 | 36.88 |
| <4 cycles | 312/2580 | 12.10 |
| Endocrine therapy | ||
| HR-positive without endocrine therapy | 819/2511 | 52.45 |
| HR-negative with endocrine therapy | 62/673 | 9.21 |